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Background: Recent publications have questioned the 
role of orthotopic liver transplantation (OLT) in treat-
ing advanced or unresectable peripheral cholangiocar-
cinoma (Ch-Ca). 
Study Design: We reviewed our experience with Ch-Ca to 
detennine survival rates, recurrence patterns, and risk 
factors in 54 patients who underwent either hepatic 
resection or OLT between 1981 and 1994. Liver trans-
plantation was performed in patients with unresectable 
tumors (n = 12) and in those with advanced cirrhosis 
(n = 8). There were 33 women (61%) and 21 men 
(39%), with a mean age of 54.3 years. The median 
followup period was 6.8 years. Prognostic risk factors 
were analyzed by univariate and multivariate analyses. 
Results: Mortality within 30 days was 7.4%. Overall pa-
tient and tumor-free survival rates were 64 % and 57% at 
1 year, 34% and 34% at 3 years, and 26% and 27% at 5 
years after operation. Thirty-two patients (59.3%) ex-
perienced tumor recurrence. Univariate analysis re-
vealed that multiple tumors, bilobar tumor distribution, 
regional lymph node involvement, presence of metas-
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tasis, positive surgical margins, and advanced pTNM 
stages were significant negative predictors of both 
tumor-free and patient survival. Multivariate analysis 
revealed that positive margins, multiple tumors, and 
lymph node involvement were independently associ-
ated with poor prognosis. When patients with these 
three negative predictors were excluded, the patient 
survivals at I, 3, and 5 years were 74%,64%, and 62%, 
respectively. 
Conclusions: Both hepatic resection and OLT are effec-
tive therapies for Ch-Ca when the tumor can be re-
moved with adequate margins, the lesion is singular, 
and lymph nodes are not involved. (j Am ColI Surg 
1997;185:429-436. © 1997 by the American College 
of Surgeons) 
Peripheral or intrahepatic cholangiocarcinoma 
(Ch-Ca) is second (l 0-20%) only to hepatocellu-
lar carcinoma (70-80%) as the most common 
primary malignancy of the liver. Currently, non-
surgical therapeutic modalities for Ch-Ca are inef-
fective. Hepatic resection (partial hepatectomy) 
has been the con\'entional form of potentially cur-
ative treatment (1-;)): the possibility of extending 
extirpation to LOtal hepatectom\' (6-H) or upper-
abdominal exenteration (9-11) followed bv liver 
replacement has been contro\'ersial (12-16). 
The objectin' of this stud\' was to review Ollr 
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Table 1. pTN~ Pathologic Classification 
Stage 1 
Stage II 
Stage 1Il 
Stage IVA 
Stage IVB 
Tl* ''0 
T2t NO 
T1 Nlf 
T2 Nl 
T3§ NO, Nl 
HII Anv N 
AnyT AnyN 
:V1O 
:V1O 
MO 
\10 
MO 
MO 
MI' 
*Tl: solitar\', :"5 2 em, without vascul~r in~sion. . <: <) > 
'T2: solitarv. oS 2 em. with vascular invasIOn. :o.!uluple, one lobe, - _ em. 
without vascular invasion. Solitary. > 2 em, without vascular mvaslOn. 
IN!: regionaL .., . h 
!iT3: solitarv, > 2 em. with vascular mvaslon. Muluple. one lobe, > 2 em. WIt 
or without vascular invasion. 
''r4: Multiple. more than one lobe. Invasion of major branch of portal 
or hepatic veins. 
'M!: Distant metastasis. 
experience with Ch-Ca to determine s~rvival rat~s, 
recurrence patterns, and progno~tic nsk fae.tors In 
patients who had undergone hver resecuon or 
hepatic transplantation. 
Methods 
During the 14-year period of .1981-1994; 54 pa-
tients with Ch-Ca underwent eIther hepauc resec-
tion (Hx) (n = 34) or orthotopic liver transplan-
tation (OLT) (n = 20) at the University of 
Pittsburgh Medical Center. The median followup 
was 6.8 years (range, l.3-14.9 years). There were 
33 women (61 %) and 21 men (39%); ages ranged 
from 28 to 75 years (mean :±: SE, 54.3 ::±: 1l.4 
years). , . . 
Clinicopatholog;ic charactenstzcs. For thls study, 
Ch-Ca was defined as a carcinoma arising from the 
epithelium of the intrahepatic bil~ du~t (intra-
hepatic or peripheral type). For paue~ts In whom 
the anatomic classification was amblguous. the 
presence of severe epithelial dysplasia or carci-
noma in situ of the extrahepatic duct was taken as 
an indication of hilar Ch-Ca. These patients were 
not included in the studv. 
The pathology repor~ and oper~tive fi~di.ngs 
were used to determine the followmg: pnnClpal 
tumor size (diameter in cm), number of gross 
Table :!, pTNM Stages of 54 Patients With Peripheral 
Cholangiocarcinoma Treated bv Hepatic Resection 
or Transplantation 
Transplantation 
Resection OLT OLT,Cl 
pT"~1 sta((e n % II ('! (l II (~ 0 
I + II <) 26.5 :\ 15 () 
III II 32.4 ,) 10 " 10 
IVA 13 :~8.2 I, :10 l ~o 
I\"B I 2.9 I) :1 15 
()LT. onil()(oplC liver transplantauon: OI:r·CI. or\f.ln-dus[er tt .1I1Splant;uion. 
hepatic lesions (single or multiple), lobar distribu-
tion (unilobar or bilobar), vascular invasion (Vo = 
none; V 1 = microscopic; V 2 = macroscopic), lym-
phatic invasion (positive or negative), surgical 
margins (positive or negative), distant metastases 
(pre'sent or absent), and cirrhosis (present or 
absent). 
Tumor stage was defined according to the 
pTNM classification proposed by the Internati~nal 
Union Against Cancer (17) and the Amencan 
Joint Committee on Cancer (18) (Table 1). There 
were 12 patients with stage I or II tumors, 15 
patients with stage III tumors, and 27 patients with 
stage IV tumors (Table 2).. . 
Surgical procedures. For those WIth anatomIcally 
resectable tumors or for those without advanced 
cirrhosis, partial hepatectomy (Hx) was the proce-
dure of choice. Total hepatectomy with liver re-
placement (OLT) was performed when tumor ~x­
tension or underlying cirrhosis precluded parual 
hepatectomy. 
Thirty-four patients were treated with Hx: nine 
underwent left lobectomy, eight had a right lobec-
tomy, six had right trisegrnentectomy, four under-
went left trisegrnentectomy, three had an ex-
tended left lobectomy, two had an extended right 
lobectomy, and two underwent large nonanatomic 
resections. The surgical techniques of subtotal 
hepatectomy have been described elsewhere 
(19-22). 
Twenty patients were treated with OLT. Twelve 
had unresectable tumor(s) by conventional tech-
niques of subtotal hepatectomy and had transplan-
tation; eight had transplantation because of con-
comitant advanced cirrhosis. Because of highly 
unfavorable conditions such as lymph node in-
volvement or direct invasion of tumor into adja-
cent organs, an upper-abdominal exenteration 
and organ-cluster transplantation (OLT-CI) were 
performed in 9 of the 20 patients (9, 10). The 
surgical technique for OLT, including OLT-Cl, 
and the immunosuppression used thereafter have 
been described elsewhere (9, 23-25). 
Adjuvant therapy. Thirty-seven patients received 
adjuvant chemotherapy or radiation therapy be-
fore or after the operation (Table 3). Because of 
the prolonged study period. these regimens were 
highly variable. . 
Statistical anal\'sis. The results were summanzed 
as of December' 31, 1996. Cumulative overall sur-
\ival and tumor-free sllnival rates were calculated 
bv the method of Kaplan and Meier. with adjust-
!~ent for the type of operation (OLT versus Hx) 
(26). If a patient died at anv time without ttu~or 
recurrence. he or she was censored as tumor-tree 
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Table 3. Pathologic Characteristics and Univariate Analvsis of Prognostic Risk Factors 
No. Cumulative patient survival* Cumulative tumor-free survival* 
Risk factor Hx Tx Hx Tx p Value Hx Tx p Value 
Gender 
Female 23 10 18.2 = 3.4 20.2 = 1.3 > 0.41 12.0::!:: 1.2 14.6 = 2.0 > 0.52 
Male 21 10 16.2::!:: 5.9 11.3:!:4.0 23.4 = 17.2 32.1 ::!:: 16.7 
Age (y) 
s 60 16 19 16.2=5.5 20.2 ::!:: 4.5 > 0.81 6.8 = 14.9 17.7=4.1 > 0.84 
> 60 18 1 18.3 = 3.1 17.6 = 0.0 12.9 = 1.1 15.6 ::!:: 0.0 
Chemo/rads 
Yes 5 12 7.2 = 5.1 13.2 = 2.9 > 0.07 7.2 ± 4.9 32.1 = 9.1 > 0.55 
No 29 8 18.3 = 2.9 20.9 = 5.8 12.9 = 3.4 10.5 = 2.1 
Tumor size 
s 5 em 10 7 16.2 = 44.4 20.9 = 10.0 > 0.59 (73.3 :!: 28.3) (18.7 = 3.8) > 0.57 
> 5 em 24 13 18.1 = 5.1 19.2 ± 3.4 12.9 = 3.4 15.6 ± 4.1 
Tumor 
Single 19 7 77.1 =59.0 21.1 ± 10.3 < 0.014 64.5 ± 18 (68.9 = 10.4) < 0.03 
Multiple 15 13 10.1 = 4.7 19.2 = 3.4 9.0 ± 4.9 13.1 ± 3.6 
Distribution 
Unilobar 20 7 38.4 = 16.6 28.5 = 7.7 < O.Qll (60.2 = 19.5) (68.9 = 10.4) <0.03 
Bilobar 14 13 8.9 ± 1.8 17.6 ± 4.7 7.2 ::!:: 1.6 13.1 = 3.1 
Vascular invasion 
Va 10 5 77.1 = 57.1 21.1 :!: 8.6 > 0.08 (44.3 ± 12.4) (29.7 = 12.2) < 0.02 
V\ + V2 24 15 16.2 = 5.3 19.2 = 3.6 11.2 = 3.6 13.1 = 2.7 
Lymph nodes 
Negative 28 14 22,4 = 11,4 20.2 = 1.8 < 0.001 15.9 ± 8.4 32.1 = 16.6 < 0.0001 
Positive 6 6 6.5 = 2.2 6.6 ± 8.6 4.2 = 1.0 5.2 = 4.0 
Margins 
Negative 24 16 38.4 = 28.1 19.2 = 2.6 < 0.0001 23.4 ± 7.9 17.7 = 11.3 < 0.0001 
Positive 10 4 7.2 ± 1.8 0.6 ± 14.3 5.3 ± 1.2 1.5 ± 0.9 
pTNM stage 
I + II 9 3 92.1 ± 0.0 21.1 = 6.4 < 0.04 (57.9 = 13.0) (19.8 = 3.5) < 0.02 
III+rv 25 17 16.2 = 7.1 19.2 = 3.8 11.2 ± 3,4 14.6 = 3.0 
Swvival analysis with the Kaplan,Meier method with stratification by rype of surgery (eg. resection or transplant) was performed. Each statistic was computed 
separately for both types of surgery, after which the values of the observed and expected numbers of deaths in each strata were combined into the final Log·Rank 
statistic. All p values shown were obtained by this procedure. 
'Median :!: SE. in months. 
Hx, hepatic resection; Tx. transplantation. 
at that time for the Kaplan-Meier method. Alter-
natively. if a patient died with tumor recurrence, 
that patient was considered an uncensored obser-
vation for the tumor-free survival analysis. Poten-
tial risk factors examined by univari~te analysis 
were age, gender, tumor size. number of lesions, 
lobar involvement, vascular invasion, lymph node 
involvement, distant metastases, pTNM stage, sur-
gical margins, presence or absence of associated 
cirrhosis of the liver, and adjuvant therapy. Values 
of p < 0.05 were considered significant. The Cox 
proportional hazard regression model was used to 
assess the relative prognostic influence on sun;val. 
Results 
Pathologic characteristics. The principal tumor size 
had a median diameter of 8.3 em (mean ~ SE. 
8.1 ~ 4.2 cm). with a range of 0.8-22 cm. Twentv-
six patients (48%) had a single tumor: the remain-
ing 28 patients (52%) had multiple tumors. The 
tumors were unilobar in 27 patients: 14 had onlv 
right lobe involvement, and 13 had only left lobe 
involvement (Table 3). 
Fifteen patients (28%) had no evidence of vas-
cular invasion (Vo), 32 patients (59%) had micro-
scopic invasion (VI), and 7 patients (13%) had 
gross vascular invasion (V2 ) of either the portal 
vein (4 patients) or the hepatic vein branches (3 
patients). 
Fourteen patients (26%) had regional lymph 
node involvement (N-I) and five (9%) had re-
gional metastatic disease (M-1) at the time of op-
eration (Table 3). All lesions were resected in 
continuity with the principal tumor. 
The margins of resection were free of tumor 
(Ro) in 40 patients. Margins were microscopically 
positive (R1 ) in 10 patients and grossly positive 
(R2 ) in the remaining 4 (Table 3). No gross tumor 
remained at the conclusion of the surgical proce-
dure in any patient. 
Eight patients in the OLT group had associated 
cirrhosis of the liver (40%), Of the 29 patients 
tested for hepatitis B \;rus. 3 had positive serology. 
432 J .-\.M COLL SeRG :'\OVEMBER 1997 \'OLU~!E 185:429-436 
_100 ~-----------------------------------------------, 
~ 
-
-;; 
;>-
.;: 80 ... 
= rIl 
co 
-- Patient (n=54) 
.~ 
.. 60 :; 
--0- Tumor-free 
E 
= U 
40 
20 
O+---~--~----~--~----~---r--------~--~--~ 
o z J 4 !i 
Years after Surgery 
FIG 1. Actuarial (overall) patient and tumor-free suIVival. 
None of the 20 patients tested was positIVe for 
hepatitis C virus. One of 20 patients tested had an 
elevated serum titer of carcinoembryonic antigen; 
3 of the 24 tested for serum alpha-fetoprotein had 
elevated levels. 
The pTNM stages of the 54 patients are summa-
rized in Tables 2 and 3. Twenty-seven patients 
(50%) presented with pTNM stage IV. 
Survival rate. The overall patient survival rates of 
the 54 patients were 64% at 1 year, 34% at 3 years, 
and 26% at 5 years after operation (Fig. 1). The 
tumor-free survival rates were 57% at 1 year, 34% 
at 3 years, and 27% at 5 years after operation 
(Fig. 1). 
The patient survival rates after Hx (60% at 1 
vear. 37% at 3 years, and 31 % at 5 years) were 
~imilar to those ;Uter OLT (70% at 1 year, 29% at 
3 years. and 18% at 5 years), as shown in Figure 2. 
Tumor-free survival after Hx (50% at 1 year, 30% 
at 3 years, and 25 % at 5 years) was also similar to 
that after OLT (67% at 1 year, 31 % at 3 years, and 
31 % at 5 years), as shown in Figure 3. The higher 
rate of tumor-free survival compared with actuarial 
patient survival reflects a high death rate without 
recurrence among patients with Ch-Ca, regardless 
of the type of surgical procedure. 
As expected, the pTNM stage significantly influ-
enced both patient and tumor-free survival (Fig. 4; 
Table 3). 
Causes of death. Twenty-four of the 34 patients 
(73.5%) in the Hx group and 16 of the 20 patients 
(80%) in the OLT group were dead at the time of 
followup (December 1996). 
Four of the 54 patients died within 30 days after 
operation. giving an overall operative mortality 
rate of 7.4%. The first patient died intraopera-
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FIG 3. Actuarial tumor-free sUIvival. Hx, hepatic resection; OLT, orthotopic liver transplantation. 
tively of an irreversible arrhythmia during Hx, and 
the second patient died of sepsis and liver failure 
24 days after Hx. The third patient died of massive 
upper gastrointestinal hemorrhage 6 days after 
OLT, and the fourth patient died of rupture of a 
mycotic hepatic artery aneurysm 18 days after 
OLT. 
An additional six patients died of causes unre-
lated to Ch-Ca. One patient died of renal and 
cardiac failure 19 months after Hx, the second 
died of an unknown sudden cause 6 years after 
Hx, and the third patient died of pancreatic can-
cer 14 years after Hx. The fourth patient died of 
acute pulmonary tuberculosis 5 months after 
OLT. the fifth patient died of aspergillosis 14 
months after OLT, and the sixth died of recurrent 
hepatitis B 22 months after OLT. 
A total of 30 patients died with recurrent Ch-Ca, 
19 (55%) in the Hx group and 11 (56%) in the 
OLT group. The higher 5-year tumor-free survival 
in the OLT group relative to the Hx group (31 % 
and 25%, respectively) was due to the low rate of 
tumor recurrence among the 9 OLT-Cl patients 
(Fig. 3). 
Prognostic factors. The influence of the 12 clini-
copathologic factors on tumor-free and overall pa-
tient survival was examined by univariate analysis 
(Table 3). Multiple gross tumors, a bilobar tumor 
distribution, regional lymph node involvement, 
the presence of metastasis. positive surgical mar-
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FIG 5. Actuarial patient and tumor·free survival of low- and high-risk groups. 
gins, and advanced (III and IV) pTNM stages were 
statistically significant negative prognostic factors 
for both tumor-free and overall patient survival. 
The presence of vascular invasion was a statistically 
significant factor reducing the tumor-free survival, 
but it did not influence the overall patient survival. 
Age, gender, size of principal tumor, associated 
cirrhosis, and adjuvant chemotherapy did not in-
fluence either tumor-free or patient survival. 
Because positive metastasis turned out to be 
uniformly fatal (all five patients died within 1.3 
years) (p < 0.001), this prognostic factor was ex-
cluded from the multivariate analysis. Of the six 
prognostic factors that reached statistical signifi-
cance in the univariate analysis, the multivariate 
analysis revealed positive margins, multiple tu-
mors. and lymph node involvement to be indepen-
dently associated with a poor prognosis both for 
patient and for longterm (more than one year) 
tumor-free survival. For patient survival, the rela-
tive hazards for positive margins. multiple tumors, 
and lymph node involvement were 1.74, 1.63, and 
1.60, respectively. For tumor-free survival, the rel-
ative hazards for positive margins. multiple tu-
mors. and lymph node involvement were 8.2, 2.0, 
and 2.65, respectively. These statistics show the 
hazard of death or tumor recurrence at any given 
time point. 
There were 21 patients (15 in the Hx group and 
6 in the OLT group) in whom none of these three 
negative predictors was present. The actuarial pa-
tient and tumor-free survival rates of these 21 pa-
tients (low-risk group) were 7--1% and 79% at I 
vear, 64% and 62% at 3 vears, and 64% and 52% 
:It 5 vears, respectively (Fig. 5). Conversely, in the 
:~3 patients (19 in the Hx group and l4: in OLT 
group) in whom at least one of these three nega-
tive predictors was present (high-risk group), pa-
tient and tumor-free survival rates were 58% and 
43% at 1 year, 18% and 13% at 3 years, and 9% 
and 13% at 5 years after operation (p < 0.0001) 
(Fig. 5). 
Tumor recurrence. Recurrence of Ch-Ca was con-
firmed in 32 of the 54 patients (59%) during the 
study period: 21 of the 34 patients (62%) in the 
Hx group and 11 of the 20 (55%) in the OLT 
group (2 patients are currendy alive with disease). 
Tumor recurrence was diagnosed within 1 year 
after operation in 21 patients (66%) and within 2 
years in 29 patients (91 %). Only one patient with 
recurrence had it after 3 years; this patient was in 
the resection group and suffered recurrence at 4.3 
years. Overall, there was no difference in time to 
recurrence between Hx and OLT. 
The liver was the most common site of tumor 
recurrence (20 patients), followed by the lung (18 
patients), the bones (7 patients), and other sites 
such as the peritoneum, adrenal gland, and kid-
ney (5 patients). 
Five-year suroivors. Of the 39 patients with ~ 5 
years of followup, 9 (23%) survive: 6 of 21 (29%) 
in the Hx group and 3 of 18 (17%) in the OLT 
group. Seven of these 9 patients had a single tu-
mor: 6 had a unilobar tumor distribution, and 7, 
surprisingly, had a principal tumor size of> 5 cm. 
Four of the 9 patients had microscopic vascular 
invasion. Four of the 9 patients were classified as 
pTNM stage I or II. 3 patients as stage III, and 2 
patients as stage IVA. 
None of the 5-vear survivors had positive mar-
brins. regional metastasis. lymph node involve-
ment. or macroscopic \'ascular rumor invasion. All 
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three patients in the OLT group who survived> 5 
years were classified as p TNM stage III or IVA and 
underwent OLT-Cl. Two of the 5-vear survivors 
(both in the Hx group) had tumor recurrence in 
the liver 2 and 4 years after Hx and undenvent 
repeat surgical resection. 
Discussion 
Cholangiocarcinoma is a cancer arising from the 
epithelium of the biliary ducts. The bile duct lo-
cated on the hepatic side of the first intrahepatic 
branch of the right and left hepatic duct is con-
sidered "intrahepatic" or "peripheral." The re-
maining part of the bile duct is considered "extra-
hepatic," including the hilum of the liver. In the 
strictest sense, then, Ch-Ca is a cancer arising from 
the epithelium of the intrahepatic duct or 
ductules (27-29). Practically speaking, differenti-
ation of intrahepatic from extrahepatic bile duct 
cancer is often difficult anatomically, particularly 
in the hepatic hilum, and the histologic character-
istics of the two are identical. For these reasons, 
cancers arising from the epithelium of the right 
and left hepatic ducts and the bifurcation are also 
called Ch-Ca of "hilar" or "central" type (Klatskin 
tumor) (30). 
This article reports the prognostic risk factors 
and outcomes of 54 patients with Ch-Ca who un-
derwent aggressive surgical therapy at our institu-
tion. To our knowledge, this study represents the 
largest series of patients with peripheral Ch-Ca 
who were treated with Hx or OLT at a single 
institution. These two groups of patients treated 
with two different surgical procedures are not 
strictly comparable because Hx was considered the 
surgical procedure of choice for resectable Ch-Ca. 
and OLT was performed when patients had either 
unresectable tumors or associated cirrhosis. It was 
surprising, then. to find that even though a signif-
icantly greater number of patients in the OLT 
group had advanced malignant disease than in the 
Hx group (65% versus 41%), as represented by 
stage IV disease (Table 2), the longterm tumor-
free and patient survival rates were similar for the 
two groups. Although patient survival at 5 years 
was greater in the Hx group. the 5-vear tumor-free 
sunival was greater in the 0 L T group (31 % versus 
25%). despite the more advanced disease. The 
dramatic decrease in sunival for the OL T group 
between :> and 5 years was due to two deaths 
related to earlv recurrence. 
This studv c'ontirmed the general opinion (13. 
1-1. 31. 32) that postoperative recurrence rates and 
stlnival of patients "ith Ch-Ca are determined bv 
pTNM stage. The median survival after Hx or OLT 
for tumor stages I and II combined. III. and IV was 
77, 18. and 17.5 months, respectively. The actuar-
ial 1-, 3-, and 5-year patient survival rates were 
90%, 70%, and 70% for stages I and II; 60%. 
33.3%, and 25% for stage III: and 55.6%, 21.6%, 
and 13% for stage IV. These rates are consistent 
with previous reports of patients undergoing liver 
resection for Ch-Ca (3, 13, 14). Unfortunately, an 
accurate analogy with published data for patients 
who underwent OLT for Ch-Ca is extremely diffi-
cult to make because case material was small (12. 
14, 31, 32), results were not stratified according to 
specific stages (31-33), or the two distinctive types 
of Ch-Ca (peripheral versus hilar) were combined 
in the analysis (12). 
The actuarial survival of patients undergoing 
Hx or OLT for Ch-Ca, reported in this study, is 
comparable to our results (34) using similar sur-
gical treatment in patients with hepatocellular car-
cinoma at equivalent stages. There were more 5-
year survivors treated for Ch-Ca than those treated 
for hepatocellular carcinoma (23% versus 14%, 
respectively). Positive tumor margins and lymph 
node metastasis were prognostic risk factors asso-
ciated with significantly poorer survival rates for 
both types of malignancies. 
The results of this study suggest. in contrast to 
reports in the literature, that OLT should not be 
eliminated in the treatment of Ch-Ca. In fact, 
based on our identification of a selected group of 
patients found to have an "acceptable" longterm 
survival, an argument could be made for expand-
ing its role if there is a sufficient supply of donor 
organs. At least one group has questioned whether 
OLT-Cl is of any value for the treatment of hepa-
tobiliary malignancies in general (16). Although 
there is limited experience with the cluster proce-
dure for the specific indication of Ch-Ca, our only 
patients with Ch-Ca in the OLT group who sur-
vived > 5 years had undergone OLT-Cl. Of nine 
patients who underwent OLT-Cl, only four had 
recurrent disease during the study period. 
Our multivariate analysis revealed that. in addi-
tion to metastatic disease. positive surgical mar-
gins. multiple gross tumors. and lymph node in-
\'olvement were independent risk bctors for poor 
sllrvival after both Hx and OLT in patients with 
eh-Ca. Converseiv. the actuarial 1-. 3-. and 5-vear 
survival rates of patients with none of these three 
negative predictors were signiticallllv higher than 
those of patients with at least one of these risk 
factors (7-1.2%. 66.5%. and 66.5% \ersus 58%. 
18%. and 9%. respectiveiv). Because we did not 
find anv difference in time to recurrence between 
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the Hx and OLT groups, our results do not sup-
port the hypothetical (and logical) contention 
that immunosuppression shortens the tumor-free 
interval rate. The indications for OLT can reason-
ably include at least some appropriately staged 
patients with Ch-Ca. 
In conclusion, these data suggest that Hx and 
OLT are both defensible options for patients with 
Ch-Ca who have single lesions, negative lymph 
nodes, and surgically resectable disease. Identifi-
cation of risk factors, which predict prognosis, 
requires extensive preoperative and intraoperative 
evaluations. Because the number of patients un-
dergoing surgical therapy for this disease is so 
small, a multiinstitutional study is needed to assess 
the relative efficacy of Hx, conventional OLT, or 
even upper-abdominal exenteration and OLT 
(OLT-Cl). Conceivably, the indications for con-
ventional OLT or OLT-Cl should be broadened to 
include some of the patients with advanced dis-
ease who are currently being treated with Hx. 
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